Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).

Andrew M. Evens,Fangxin Hong,Thomas Matthew Habermann,Ranjana H. Advani,Randy D. Gascoyne,Thomas Elmer Witzig,Andrew Quon,Lynne I. Wagner,Stephen Maxted Ansell,Adam M. Petrich,Julie E. Chang,Timothy E. O'Brien,Puneet S. Cheema,Terrence Cescon,Keren Sturtz,Brad S. Kahl

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).

2016

Andrew M. Evens
Fangxin Hong
Thomas Matthew Habermann
Ranjana H. Advani
Randy D. Gascoyne
Thomas Elmer Witzig
Andrew Quon
Lynne I. Wagner
Stephen Maxted Ansell
Adam M. Petrich
Julie E. Chang
Timothy E. O'Brien
Puneet S. Cheema
Terrence Cescon
Keren Sturtz
Brad S. Kahl

7507Background: Treatment strategies to improve outcomes in HR FL are needed. E2408 tested whether bortezomib (V) improves the CR rate when added to standard BR induction in untreated HR FL and whe...

Keywords:

Oncology
Pathology
Follicular lymphoma
Bendamustine/rituximab
Bortezomib
Internal medicine
Medicine
Surgery
treatment strategy
complete remission

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations